Kissei Pharmaceutical Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Kissei Pharmaceutical heeft een totaal eigen vermogen van ¥220.8B en een totale schuld van ¥1.3B, wat de schuld-eigenvermogensverhouding op 0.6% brengt. De totale activa en totale passiva bedragen respectievelijk ¥260.3B en ¥39.6B. De EBIT Kissei Pharmaceutical is ¥3.8B waardoor de rentedekking -2.9 is. Het heeft contanten en kortetermijnbeleggingen van ¥50.0B.

Belangrijke informatie

0.6%

Verhouding schuld/eigen vermogen

JP¥1.26b

Schuld

Rente dekkingsratio	-2.9x
Contant	JP¥49.96b
Aandelen	JP¥220.77b
Totaal verplichtingen	JP¥39.57b
Totaal activa	JP¥260.34b

Recente financiële gezondheidsupdates

Geen updates

Recent updates

Kissei Pharmaceutical (TSE:4547) Will Pay A Larger Dividend Than Last Year At ¥45.00

Sep 24

Kissei Pharmaceutical (TSE:4547) Is Increasing Its Dividend To ¥45.00

Sep 09

Kissei Pharmaceutical's (TSE:4547) Dividend Will Be Increased To ¥45.00

Jul 25

Kissei Pharmaceutical (TSE:4547) Will Pay A Larger Dividend Than Last Year At ¥45.00

Jul 11

Kissei Pharmaceutical's (TSE:4547) Shareholders May Want To Dig Deeper Than Statutory Profit

May 21

Kissei Pharmaceutical Co., Ltd. (TSE:4547) Yearly Results: Here's What Analysts Are Forecasting For This Year

May 09

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( ¥107.0B ) 4547 } overtreffen de korte termijn passiva ( ¥19.4B ).

Langlopende schulden: De kortetermijnactiva 4547 ( ¥107.0B ) overtreffen de langetermijnschulden ( ¥20.1B ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: 4547 heeft meer geld in kas dan de totale schuld.

Schuld verminderen: De schuld/eigen vermogen-ratio van 4547 is de afgelopen 5 jaar gedaald van 2% naar 0.6%.

Schuldendekking: De schuld van 4547 wordt goed gedekt door de operationele kasstroom ( 272.3% ).

Rentedekking: 4547 verdient meer rente dan het betaalt, dus de dekking van rentebetalingen is geen probleem.

Kissei Pharmaceutical Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Recent updates

Second quarter 2025 earnings: EPS misses analyst expectations

Kissei Pharmaceutical Co., Ltd. (TSE:4547) announces an Equity Buyback for 1,400,000 shares, representing 3.17% for ¥5,292 million.

Kissei Pharmaceutical (TSE:4547) Will Pay A Larger Dividend Than Last Year At ¥45.00

Upcoming dividend of JP¥45.00 per share

Kissei Pharmaceutical (TSE:4547) Is Increasing Its Dividend To ¥45.00

Kissei Pharmaceutical Co., Ltd. to Report Q2, 2025 Results on Nov 05, 2024

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Kissei Pharmaceutical's (TSE:4547) Dividend Will Be Increased To ¥45.00

Kissei Pharmaceutical (TSE:4547) Will Pay A Larger Dividend Than Last Year At ¥45.00

Final dividend of JP¥45.00 announced

Kissei Pharmaceutical Co., Ltd. to Report Q1, 2025 Results on Jul 30, 2024

Kissei Pharmaceutical's (TSE:4547) Shareholders May Want To Dig Deeper Than Statutory Profit

Kissei Pharmaceutical Co., Ltd. (TSE:4547) Yearly Results: Here's What Analysts Are Forecasting For This Year

Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Kissei Pharmaceutical Co., Ltd., Annual General Meeting, Jun 25, 2024

Kissei Pharmaceutical (TSE:4547) Is Due To Pay A Dividend Of ¥41.00

Upcoming dividend of JP¥41.00 per share

Kissei Pharmaceutical (TSE:4547) Is Due To Pay A Dividend Of ¥41.00

Kissei Pharmaceutical Co., Ltd. to Report Fiscal Year 2024 Results on May 07, 2024

Kissei Pharmaceutical (TSE:4547) Has Announced A Dividend Of ¥41.00

Third quarter 2024 earnings released: EPS: JP¥59.18 (vs JP¥72.45 in 3Q 2023)

Kissei Pharmaceutical Co., Ltd. Provides Dividend Guidance for the Year Ending March 2024

New major risk - Revenue and earnings growth

Price target increased by 7.4% to JP¥3,650

Kissei Pharmaceutical Co., Ltd. and Maruishi Pharmaceutical Co., Ltd. Announces KORSUVA®? IV Injection Syringe for Dialysis 17.5ug, 25.0ug to Launch in Japan for Treatment of Pruritus in Patients Undergoing Hemodialysis

Consensus EPS estimates fall by 10%

Kissei Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Jan 30, 2024

Now 20% undervalued after recent price drop

Second quarter 2024 earnings released: EPS: JP¥52.66 (vs JP¥36.67 in 2Q 2023)

Now 20% undervalued after recent price drop

Price target increased by 7.1% to JP¥3,400

Kissei Pharmaceutical Co., Ltd. Revises Consolidated Earnings Guidance for the First Half Ending September 30, 2023

Upcoming dividend of JP¥41.00 per share at 2.4% yield

Price target increased by 8.9% to JP¥3,350

Kissei Pharmaceutical Co., Ltd. to Report Q2, 2024 Results on Nov 07, 2023

Investor sentiment improves as stock rises 17%

New minor risk - Share price stability

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Kissei Pharmaceutical Co., Ltd. Announces Withdrawal of Application for Marketing Approval for Rovatirelin for the Treatment of Spinocerebellar Degeneration in Japan

Full year 2023 earnings: EPS and revenues miss analyst expectations

Kissei Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Jul 31, 2023

Kissei Pharmaceutical Co., Ltd., Annual General Meeting, Jun 22, 2023

Full year 2023 earnings: EPS and revenues miss analyst expectations

Kissei Pharmaceutical Co., Ltd. (TSE:4547) announces an Equity Buyback for 2,000,000 shares, representing 4.34% for ¥6,000 million.

Upcoming dividend of JP¥40.00 per share at 3.1% yield

Kissei Pharmaceutical Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023

Third quarter 2023 earnings released: EPS: JP¥72.45 (vs JP¥25.00 in 3Q 2022)

Consensus forecasts updated

Now 20% undervalued

Kissei Pharmaceutical Co., Ltd. Receives Marketing Authorization Approval in Japan for TAVALISSE Tab. 100Mg and 150Mg, an Oral Spleen Tyrosine Kinase Inhibitor

Kissei Pharmaceutical Co., Ltd. to Report Q3, 2023 Results on Jan 31, 2023

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Less than half of directors are independent

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Kissei Pharmaceutical Co., Ltd. Announces Dividend for the Second Quarter and Dividend Guidance for Year Ending of March 31, 2023, Payable Date on December 2, 2022

Kissei Pharmaceutical Co., Ltd. Revises Consolidated Earnings Guidance for the First Half Ending September 30, 2022

Upcoming dividend of JP¥40.00 per share

Kissei Pharmaceutical Co., Ltd. to Report Q2, 2023 Results on Nov 08, 2022

Kissei Pharmaceutical Co., Ltd. Provides Earning Guidance for the First Half Ending September 30, 2022 and Full Year Ending March 31, 2023

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment deteriorated over the past week

Consensus forecasts updated

Kissei Pharmaceutical Co., Ltd. to Report Q1, 2023 Results on Aug 01, 2022

Consensus forecasts updated

Kissei Pharmaceutical Co., Ltd., Annual General Meeting, Jun 23, 2022

Full year 2022 earnings: EPS exceeds analyst expectations

Kissei Pharmaceutical Co., Ltd. to Report Fiscal Year 2022 Results on May 10, 2022

Upcoming dividend of JP¥28.00 per share

Third quarter 2022 earnings: EPS exceeds analyst expectations

Kissei Pharmaceutical Co., Ltd. Releases Positive Topline Results from Its Phase 3 Clinical Trial in Japan

Second quarter 2022 earnings released: EPS JP¥43.85 (vs JP¥57.18 in 2Q 2021)

Kissei Pharmaceutical Co., Ltd. announces approval for TAVNEOS® (avacopan) for the treatment of ANCA-associated vasculitis in Japan

Upcoming dividend of JP¥28.00 per share

Price target increased to JP¥2,980

First quarter 2022 earnings released: EPS JP¥79.02 (vs JP¥36.93 in 1Q 2021)